News

News and Press Releases
Clinical Trials Anti-Inflammatory Drug for CF Fails to Meet Goal of Late-Stage Clinical Trial

Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.

| 2 min read
Drug Pipeline | Clinical Trials Vertex Announces Positive Study Results for Trikafta in Children Ages 6-11

Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.

| 2 min read
Research | About the CF Foundation | Clinical Trials | Our Research Approach CF Foundation Announces up to $5M Award to Support First-Ever Controlled Clinical Study of Phage Therapy in Cystic Fibrosis

Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF

| 4 min read
Research | Clinical Trials | Our Research Approach CF Foundation Awards Funding for First-Ever Controlled Clinical Study of Phage Therapy in CF

The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.

| 3 min read